Sirnaomics Ltd. (HK:2257) has released an update.
Sirnaomics Ltd. has reported positive interim results from the second cohort of its Phase I clinical trial of STP122G, a novel GalNAc-based RNAi therapeutic aimed at anticoagulation by targeting Factor XI. The trial, which involved eight healthy participants receiving a 50 mg dose, displayed no serious adverse events or dose-limiting toxicities, showing promise for a safer anticoagulation treatment. While the company proceeds with further study cohorts, investors are cautioned as the drug’s market success is not guaranteed yet.
For further insights into HK:2257 stock, check out TipRanks’ Stock Analysis page.
